The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR:: ABL1 tyrosine kinase inhibitors
The BCR:: ABL1 tyrosine kinase inhibitors (TKIs) have improved the outcomes of patients
with chronic myeloid leukemia (CML). After failing second‐generation TKI (2G‐TKI), the …
with chronic myeloid leukemia (CML). After failing second‐generation TKI (2G‐TKI), the …
Navigating the Management of Chronic Phase CML in the Era of Generic BCR:: ABL1 Tyrosine Kinase Inhibitors
FG Haddad, H Kantarjian - Journal of the National Comprehensive …, 2024 - jnccn.org
Over the past several years, advances in research, treatment, and market dynamics have
impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They …
impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They …
A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia
S Galimberti, E Abruzzese, G Luci, C Baratè, L Luciano… - Pharmaceutics, 2024 - mdpi.com
Ponatinib may be effective in chronic myeloid leukemia (CML) patients after failure of
first/second line therapies. Although its efficacy for minimum plasma concentrations (Cmin) …
first/second line therapies. Although its efficacy for minimum plasma concentrations (Cmin) …
Emerging roles of circRNAs in leukemia and the clinical prospects: An update
W Deng, R Chao, S Zhu - Immunity, Inflammation and Disease, 2023 - Wiley Online Library
Abstract Background Circular RNAs (circRNAs) are a new category of endogenous non‐
protein coding RNAs (ncRNAs), and show the characteristics of high conservation, stability …
protein coding RNAs (ncRNAs), and show the characteristics of high conservation, stability …
[PDF][PDF] Pharmacogenetic and liquid biopsy: The new tools of precision medicine in cancer. INNOSC Theranostics and Pharmacological Sciences
VA Alonso, A Lazarowski - 2023 - api-journal.accscience.com
The main difficulty in the treatment of cancer lies in the already known mechanism of
resistance to conventional chemotherapy. It is mainly due to the expression of the multidrug …
resistance to conventional chemotherapy. It is mainly due to the expression of the multidrug …
Pharmacogenetic and liquid biopsy: The new tools of precision medicine in cancer
VA Alonso, A Lazarowski - INNOSC Theranostics and …, 2023 - accscience.com
The main difficulty in the treatment of cancer lies in the already known mechanism of
resistance to conventional chemotherapy. It is mainly due to the expression of the multidrug …
resistance to conventional chemotherapy. It is mainly due to the expression of the multidrug …